JAK/TYK2
3 years 6 months ago
EULAR 2021 - Day 2 Podcasts
Check out this compilation of our EULAR 2021 Day 2 broadcasts below.
You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.
https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
3 years 6 months ago
Looking at those results (distributed evenly each side of 'maybe a little') it seems we're collectively uncertain right now about what JAK1 selectivity really means in practice.
Hopefully we get stronger clinical insights (toxicity/efficacy) in coming years!
#EULAR2021 @RheumNow https://t.co/jFhVGqpOnb
3 years 6 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow & its Faculty.
3 years 6 months ago
#EULAR2021 and EULAR IQ
Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.
https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
3 years 6 months ago
RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, & Janssen. All content chosen by RheumNow & its Faculty.
3 years 6 months ago
Is #JAKi better on PROs than #Adalimumab in MTX-IR pts with RA? Yes....some. RA BEAM with 4mg Bari >Adalimumab for pain, HAQ, am stiffness but = on fatigue. POS0649 @RheumNow @eular_org #EULAR2021
3 years 6 months ago
2021 GRAPPA STRONG recs (cont'd):
*⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i
🚫strong rec against IL17i
2021 GRAPPA CONDITIONAL recs for:
*⃣ Uveitis: TNFi (not ETN), CyA
*⃣ Crohn's Dz & UC: IL23i, JAKi, MTX
OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG